ArticleWorld journal of surgical oncology2026
LncRNA miR17HG promotes tumor progression through AXIN2 by sponging miR-144-3p in bladder cancer.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAccumulating evidence indicates that long non-coding RNA (lncRNA) miR17HG plays important roles in tumorigenesis in various cancers. However, its underlying effect on bladder cancer (BC) remains to be explored.
objectiveThis study aims to elucidate the function and molecular mechanisms of lncRNA miR17HG in the proliferation and metastasis of BC.
methodsBC tissues and matched para-cancerous tissues were collected from our hospital. Oncology functional assays, quantitative reverse-transcription polymerase chain reaction, and western blotting were conducted to confirm the role of lncRNA miR17HG in BC development. The interations among lncRNA miR17HG, miR-144-3p and AXIN2 were verified via luciferase reporter assay. Nude mouse subcutaneous tumor models were established to investigate the effect of lncRNA miR17HG on BC tumor growth.
resultsLncRNA miR17HG and miR-144-3p were significantly upregulated, while AXIN2 was downregulated in BC tissues. Knockdown of lncRNA miR17HG or inhibition of miR-144-3p suppressed cell proliferation, migration and invasion, whereas miR-144-3p mimic exerted the opposite effects. Mechanistically, lncRNA miR17HG sponged miR-144-3p to regulate the expression of AXIN2. Furthermore, lncRNA miR17HG knockdown effectively suppressed tumor xenograft growth in mice.
conclusionIn summary, this study identifies a novel lncRNA miR17HG/miR-144-3p/AXIN2 pathway in BC and demonstrate that this regulatory axis may serve as a promising therapeutic target for BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.